Berna Biotech Pharma GmbH
SWITZERLAND
>100
Years
Experience
12
Own
Vaccine strains
3
Eminent
Scientists
Berna Biotech Pharma GmbH is a renewal of the former Berna Biotech Ltd. This company was the former Swiss Serum and Vaccine Institute founded in 1898, renamed to Berna Biotech Ltd. in 2001. It was a listed company (Swiss Exchange) and one of the top 5 companies globally active in the vaccine business producing more than 20 different vaccines and present in all markets of the world.
With the young Berna Biotech Pharma GmbH we will revive this vaccine giant with the know-how of the former R&D Lead of Berna Biotech Ltd. and the same strains.
OUR VISION
Berna Biotech Ltd. was a listed company (Swiss Exchange) and one of the top 5 companies globally active in the vaccine business producing more than 20 different vaccines. The company was present in all markets of the world.
Today our “Phoenix” project is to revive this vaccine giant with the know-how of the former R&D Lead of Berna Biotech Ltd and the same strains.
KEY PLAYER
Be a key player with sustainable profit in the fight against epidemics, with high quality vaccines and immunotherapeutics
INNOVATION PARTNER
Be a recognized innovation partner in the fight against infectious and chronic diseases
PRODUCER
To build a vaccine manufacturing plant in Switzerland producing with high level technology to be able to produce our own vaccines in Switzerland
OUR MISSION
Focus the R&D efforts on highly innovative vaccines and monoclonal antibodies
Build a state-of-the-art multipurpose production facility with a high degree of automation using the most advanced digital and data-driven technologies to:
-
tackle the issue of vaccine shortages and therefore save lives,
-
respond faster to new epidemics or pandemics,
-
expand the life-saving impact of vaccines around the world,
-
be a major supplier for WHO efforts to eradicate some viral diseases
Operate our business in an ethical manner with unwavering commitment to honesty, integrity and respect our environment
OUR TEAM
Besides Dr. Ing. Michael Claus Kuhn the team consists of the eminent scientist Prof. Dr. Philippe Paroz who is acting as Chief Scientific Officer and who has a long-standing experience in R&D, production and quality-control of a broad range of vaccines, including implementing vaccine production facilities.